Merck blood clot drug in limbo after mixed results

.

Merck blood clot drug in limbo after mixed results

On Saturday, drug-maker Merck & Co provided details about the last month-announced results of the tests of its experimental blood thinner `vorapaxar', revealing that despite the impressive effectiveness of the blood clot drug in bringing about a significant reduction in cardio vascular incidents in heart patients, worrisome bleeding was also witnessed in people who had suffered a stroke.

According to Merck, while the experimental drug, when combined with standard care, proved effective in bringing down the instances of cardio vascular events in heart patients, it also led to increased bleeding in some patients.

When Merck presented limited data from the study in February this year, the company had said that vorapaxar was proving to be an advantageous drug for heart patients. However, the drug-maker has now revealed that patients who had been administered vorapaxar were also experiencing excessive bleeding.

The Merck revelation, based on the results of the biggest heart-drug studies conducted thus far, implies that the vorapaxar blood clot preventer has shown mixed results; and has thus led to concerns whether the drug-maker will go ahead and seek regulatory approval for the drug.

Noting that the vorapaxar trial shows that there is "clearly a tradeoff here between the protective benefit and the risk of bleeding," Dr. David Morrow - who is a cardiologist from Brigham & Women's Hospital in Boston, and the leader of the trial - said: "Should the drug be approved, he said the challenge for doctors would be to withhold it from patients at likely higher bleeding risk."


Latest News

DoubleLine Capital Sold Off All its European Equities Holdings following a Huge
Qualcomm Files Complaint against Meizu with Beijing Authorities over Intellectua
Barnes & Noble Broadening its Business Model Venturing into a Beer and Wine Stor
Will Result of the Brexit Vote Reflect in the U.S. Presidential Elections? A Que
Report Shows Large Number of Americans still Prefer Receiving Credit Card Statem
U.S. Big Banks Pass Annual Stress Test
Viacom’s Board will Remain as it is for the Time being, Judge Sets Hearing for J
Crude Stockpiles Drop in the U. S
A New Study Highlights that U. S. Expected to Spend $2.6 Trillion Less than Esti
SolarCity Shares Soar with Tesla's Bid for the Company
The Leave as well as Remain Camps Gathers Pace in Brexit
Oil’s Advance Halts as Market Awaits U.S Stock Pile Data and Brexit Poll